Format

Send to

Choose Destination
Am Soc Clin Oncol Educ Book. 2017;37:495-503. doi: 10.14694/EDBK_175401.

Novel Therapeutics in Acute Myeloid Leukemia.

Author information

1
From the Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Department of Medicine, Stanford University School of Medicine, Stanford, CA.

Abstract

In this review, we focus on three key areas in acute myeloid leukemia (AML) developmental therapeutics: FLT3 inhibitors, IDH inhibitors, and drugs that may be particularly beneficial in secondary AML.

PMID:
28561688
DOI:
10.1200/EDBK_175401
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center